Aquestive Therapeutics (AQST) News Today $3.42 +0.08 (+2.24%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AQST Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Aquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday.June 17 at 8:34 AM | marketbeat.comBrokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) PT at $10.14June 17 at 2:43 AM | americanbankingnews.comAquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic ReactionsJune 16 at 8:44 AM | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by AnalystsShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price oJune 14, 2025 | marketbeat.comCantor Fitzgerald Forecasts AQST FY2026 EarningsJune 13, 2025 | americanbankingnews.comCantor Fitzgerald Predicts AQST FY2026 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Aquestive Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will eaJune 11, 2025 | marketbeat.comAquestive Therapeutics: Anaphylm Could Gain Significant Market ShareJune 9, 2025 | seekingalpha.comAquestive Therapeutics (NASDAQ:AQST) Coverage Initiated by Analysts at OppenheimerOppenheimer assumed coverage on shares of Aquestive Therapeutics in a research report on Monday. They set an "outperform" rating and a $7.00 price target on the stock.June 2, 2025 | marketbeat.comBank of America Corp DE Boosts Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Bank of America Corp DE increased its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 905.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 690,284 shares of the company's stock after purchasing an additional 621,614 shares during the peJune 2, 2025 | marketbeat.comWoodline Partners LP Reduces Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Woodline Partners LP trimmed its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 49.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 409,314 shares of the company's stock after selling 406,93May 27, 2025 | marketbeat.comThose who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128%May 26, 2025 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by VR Adviser LLCVR Adviser LLC trimmed its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 52.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,629,786 shares of the company's stock after selMay 22, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Buy" by AnalystsShares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average tweMay 22, 2025 | marketbeat.comAquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside PotentialMay 21, 2025 | insidermonkey.comStonepine Capital Management LLC Acquires New Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Stonepine Capital Management LLC acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 160,000May 20, 2025 | marketbeat.comQ2 EPS Forecast for Aquestive Therapeutics Cut by AnalystAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now expects that the companyMay 20, 2025 | marketbeat.comMPM Bioimpact LLC Has $5.74 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)MPM Bioimpact LLC cut its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,611,833 shares of the company's stock after selling 184,917May 16, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPSAquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07).May 14, 2025 | marketbeat.comAquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ...May 14, 2025 | finance.yahoo.comAquestive Therapeutics’ Q1 2025: Focus on AnaphylmMay 14, 2025 | tipranks.comEarnings To Watch: Aquestive Therapeutics Inc (AQST) Reports Q1 2025 ResultMay 13, 2025 | finance.yahoo.comAquestive Therapeutics' Shares Fall to 52-Week Low on 1Q Results, Outlook CutMay 13, 2025 | marketwatch.comAquestive Therapeutics targets $44M–$50M revenue in 2025 as Anaphylm launch preparations accelerateMay 13, 2025 | msn.comAquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deAquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | finance.yahoo.comAquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRaymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 139,591 shares of the company's stock, valued at approximately $498,000. RaMay 11, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by DAFNA Capital Management LLCDAFNA Capital Management LLC lessened its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 78.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 127,000 shares of the company's stock after selling 462,561 shares during the periodMay 10, 2025 | marketbeat.comStifel Financial Corp Buys 302,617 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)Stifel Financial Corp lifted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 315.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 398,561 shares of the company's stock after purchasing an additional 302,617 shares during theMay 10, 2025 | marketbeat.com1AQST : Uncovering Potential: Aquestive Therapeutics's Earnings PreviewMay 9, 2025 | benzinga.comInvesco Ltd. Reduces Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Invesco Ltd. cut its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 93.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,944 shares of the company's stock after selling 738,635 shares during the quarterMay 6, 2025 | marketbeat.comJPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)JPMorgan Chase & Co. cut its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 80.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,500 shares of the company's stMay 5, 2025 | marketbeat.comAquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside PotentialMay 4, 2025 | seekingalpha.comAquestive Therapeutics (AQST) Expected to Announce Earnings on TuesdayAquestive Therapeutics (NASDAQ:AQST) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-aquestive-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comAquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ETMay 1, 2025 | globenewswire.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating tApril 27, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Holdings Lowered by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP lowered its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 26.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 900,000 shares of the company's stockApril 26, 2025 | marketbeat.comFranklin Resources Inc. Reduces Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Franklin Resources Inc. decreased its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,134,796 shares of the company's stock afApril 12, 2025 | marketbeat.comAquestive Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumApril 9, 2025 | globenewswire.comRaymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 139,591 shares of the company's stock, valuedApril 9, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for AQST Q1 Earnings?Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Aquestive Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings perApril 8, 2025 | marketbeat.comAquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual FilmApril 3, 2025 | seekingalpha.comAquestive Therapeutics (AQST) Gets a Buy from Lake StreetApril 2, 2025 | markets.businessinsider.comAquestive announces positive results from pediatric study for AnaphylmApril 2, 2025 | markets.businessinsider.comAquestive completes marketing application for Anaphylm in U.S.April 1, 2025 | msn.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Position Lowered by Everstar Asset Management LLCEverstar Asset Management LLC trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 46.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 216,223 shares of the company's stock after seApril 1, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assignedMarch 31, 2025 | marketbeat.comEntryPoint Capital LLC Acquires 112,210 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)EntryPoint Capital LLC increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 475.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,797 shares of the company's stocMarch 27, 2025 | marketbeat.comAquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyMarch 25, 2025 | seekingalpha.com Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Media Mentions By Week AQST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.680.56▲Average Medical News Sentiment AQST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼83▲AQST Articles Average Week Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JANX News OCUL News VERA News ANIP News BGM News TVTX News CVAC News AMPH News CALT News GPCR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AQST Stock Free AQST Stock Alerts